Cargando…

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia (FH), do not achieve target LDL-C levels with statin mono...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Farzahna, Mansfield, Brett, Raal, Frederick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419884/ https://www.ncbi.nlm.nih.gov/pubmed/37568484 http://dx.doi.org/10.3390/jcm12155082

Ejemplares similares

ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
por: Mohamed, Farzahna, et al.
Publicado: (2022)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
por: Poirier, Steve, et al.
Publicado: (2013)

Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
por: Nava-Salazar, Sonia, et al.
Publicado: (2022)

Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
por: Lee, Chan Joo, et al.
Publicado: (2017)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Study on Regulation of Low Density Lipoprotein Cholesterol Metabolism using PCSK9 Gene Silencing: A computational Approach
por: Vijayaraghavan, Bhooma, et al.
Publicado: (2018)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
por: Zeitlinger, Markus, et al.
Publicado: (2021)

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
por: Leucker, Thorsten M., et al.
Publicado: (2018)

Candidate Gene Analysis Reveals Strong Association of CETP Variants With High Density Lipoprotein Cholesterol and PCSK9 Variants With Low Density Lipoprotein Cholesterol in Ghanaian Adults: An AWI-Gen Sub-Study
por: Agongo, Godfred, et al.
Publicado: (2020)

The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
por: Hu, Xiangming, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

Statins: are they appropriate for all patients?
por: Raal, Frederick J, et al.
Publicado: (2022)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
por: Duff, Christopher J., et al.
Publicado: (2009)

Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study
por: Ray, Kausik K, et al.
Publicado: (2022)

Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
por: Lipari, Michael T., et al.
Publicado: (2012)

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
por: Sharma, Rakesh K, et al.
Publicado: (2009)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2021)

Low density Lipoprotein cholesterol target: Changing goal posts
por: Bantwal, Ganapathi, et al.
Publicado: (2012)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
por: Hsu, Lung-An, et al.
Publicado: (2022)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
por: Rymer, Jennifer A., et al.
Publicado: (2020)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
por: Johns, Douglas G., et al.
Publicado: (2023)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
por: Ference, Brian A, et al.
Publicado: (2018)

Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography
por: Elsadek Seaoud, Elshaimaa Aly M., et al.
Publicado: (2022)

Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
por: Massy, Ziad A., et al.
Publicado: (2019)

Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population
por: Hamamura, Hitoshi, et al.
Publicado: (2021)

A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles
por: Sarkar, Samantha K., et al.
Publicado: (2020)

Low high-density lipoprotein cholesterol: current status and future strategies for management
por: Singh, Vibhuti, et al.
Publicado: (2010)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

Acute Suppurative Thyroiditis Secondary to Escherichia coli Infection
por: Siddiqui, Nida, et al.
Publicado: (2021)

A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population
por: Raal, Frederick, et al.
Publicado: (2007)

Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases
por: Matta, Anthony, et al.
Publicado: (2020)

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
por: Kapur, Navin K, et al.
Publicado: (2008)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9e96klq1brl95qu44kduqrietu